Abbott, ProMetic Pacts With Red Cross Cover Blood Screening, TSE Removal
This article was originally published in The Gray Sheet
Executive Summary
The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components
You may also be interested in...
Pall And FDA Will Discuss Studies To Support Prion Disease Filter Approval
Pall Corp. plans to meet with FDA before the end of the year to discuss what studies will be necessary to approve its prion filtration system for blood transfusion processing, the firm says
Pall And FDA Will Discuss Studies To Support Prion Disease Filter Approval
Pall Corp. plans to meet with FDA before the end of the year to discuss what studies will be necessary to approve its prion filtration system for blood transfusion processing, the firm says
J&J Cypher Royalties To Drive SurModics Projected Growth Of 20-25% In 2002
Royalties from Johnson & Johnson/Cordis' Cypher drug-eluting stent sales are expected to drive SurModics' fiscal 2002 top line growth "in the 20 to 25% range," SurModics says